Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: Insights from the Arterial Revascularisation Therapies Study, part II (ARTS II)

EuroIntervention

Volumn 5, Issue 2, 2009, Pages 190-196

  Routledge, Helen C ^a   Lefèvre, Thierry ^a   Colombo, Antonio ^b   Oldroyd, Keith G ^c   Hamm, Christian W ^d   Guagliumi, Giulio ^e   von Scheidt, Wolfgang ^f   Guetta, Victor ^g   Ruzyllo, Witold ^h   Wittebols, Kristel ⁱ   Goedhart, Dick M ^j   Serruys, Patrick W ^k  

^a INSTITUT HOSPITALIER JACQUES CARTIER   (France)

^b EMO GVM CENTRO CUORE COLUMBUS   (Italy)

^c NHS LANARKSHIRE   (United Kingdom)

^d KERCKHOFF HEART CENTER   (Germany)

^e Azienda Ospedaliera di Bergamo   (Italy)

^f KLINIKUM AUGSBURG   (Germany)

^g SHEBA MEDICAL CENTER   (Israel)

^h INSTITUTE OF CARDIOLOGY   (Poland)

ⁱ EMEA ^*  (United States)

^j CARDIALYSIS   (Netherlands)

^k ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Angioplasty; Sirolimus eluting stent; Stent thrombosis

Indexed keywords

RAPAMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; STENT THROMBOSIS; SURVIVAL RATE;

EID: 77953664768     PISSN: 1774024X     EISSN: None     Source Type: Journal    
DOI: 10.4244/EIJV5I2A30     Document Type: Article

References (18)

1. Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR Jr, Mack MJ, van den Brand M, Morel MA, Van Es GA, Kleijne J, Koglin J, Russell ME. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale and run-in phase. Am. Heart J. 2006;151:1194-204.
2. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, Cohen DJ, Mahoney E, Sleeper L, King S 3rd, Domanski M, Finlay S, Fuster, V. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am. Heart J. 2008;155: 215-23.
3. Bernardi G, Padovani R, Morocutti G, Vano E, Malisan MR, Rinuncini M, Spedicato L, Fioretti PM. Clinical and technical determinants of the complexity of percutaneous transluminal coronary angioplasty procedures: analysis in relation to radiation exposure parameters. Catheter Cardiovasc Interv. 2000;51:1-9; discussion 10.
4. Wilensky RL, Selzer F, Johnston J, Laskey WK, Klugherz BD, Block P, Cohen H, Detre K, Williams DO. Relation of percutaneous coronary intervention of complex lesions to clinical outcomes (from the NHLBI Dynamic Registry). Am J Cardiol. 2002;90:216-21.
5. Al Suwaidi J, Yeh W, Cohen HA, Detre KM, Williams DO, Holmes DR, Jr. Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). Am J Cardiol. 2001;87:1139-44.
6. Garot P, Lefevre T, Savage M, Louvard Y, Bamlet WR, Willerson JT, Morice MC, Holmes DR, Jr. Nine-Month Outcome of Patients Treated by Percutaneous Coronary Interventions for Bifurcation Lesions in the Recent Era A Report From the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial. J Am Coll Cardiol. 2005;46:606-12.
7. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB. Randomized study to evaluate Sirolimus-Eluting stents implanted at coronary bifurcation lesions. Circulation. 2004;109:1244-9.
8. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80.
9. Tsuchida K, Colombo A, Lefevre T, Oldroyd KG, Guetta V, Guagliumi G, von Scheidt W, Ruzyllo W, Hamm CW, Bressers M, Stoll HP, Wittebols K, Donohoe DJ, Serruys PW. The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II). Eur. Heart J. 2007;28: 383-5.
10. Serruys PW, Ong ATL, Morice MC, de Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Dawkins K, O'Malley J, Bressers M, Donohoe D. Arterial revascularization therapies study part II - sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. Eurointervention 2005;1:147-156.
11. Sianos G, Morel MA, Kappetein P, Morice MC, Colombo A, Dawkins K, van den Brand M, van Dyck N, Russell ME, Mohr F, Serruys PW. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. Eurointervention 2005;1:219-227.
12. Iakovou I, Ge L, Colombo A. Contemporary Stent Treatment of Coronary Bifurcation. J. Am. Coll. Cardiol. 2005;46:1446-55.
13. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
14. Iakovou I, Scmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, Predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-30.
15. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue Z, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R. Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents. Circulation. 2006;113:1108-13.
16. Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere S, Foote A, Quesada JL, Eltchaninoff H, Vanzetto G. Risk Factors for Stent Thrombosis After Implantation of Sirolimus-Eluting Stents in Diabetic and Nondiabetic Patients: The EVASTENT Matched-Cohort Registry. J Am Coll Cardiol. 2007;50:501-8.
17. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation. 2002;106(10):1205-10.
18. Bhatt DL, Topol EJ. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation. 2005;112(6):905-15.